Upholding of WARF stem cell patent reversed
By The Business Journal of Milwaukee,
The Business Journal of Milwaukee
| 05. 03. 2010
The U.S. Patent and Trademark Office's Board of Appeals and Interference has reversed an earlier decision from the Patent Office's re-examination division that upheld the claims of one of the stem cell lines held by the Wisconsin Alumni Research Foundation.
The patent covers one of the three key stem cell lines that were challenged through re-examination proceedings initiated in October 2006 at the request of consumer watchdog groups New York City-based Public Patent Foundation and the Santa Monica, Calif.-based Foundation for Taxpayer and Consumer Rights, now called Consumer Watchdog.
The re-examination division upheld the validity of the patents in mid-2008, and the groups were allowed to challenge one of the patents in an appeal to the Board of Appeals and Interference.
The groups argue that the work done by University of Wisconsin researcher James Thomson to isolate stem cell lines was obvious in the light of previous scientific research, making his work unpatentable. The groups claimed the three WARF patents were "impeding scientific progress and driving vital stem cell research overseas."
The patent office rejected the arguments by the groups...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Eric Schmidt, TIME | 04.16.2024
Imagine a world where everything from plastics to concrete is produced from biomass. Personalized cell and gene therapies prevent pandemics and treat previously incurable genetic diseases. Meat is lab-grown; enhanced nutrient grains are climate-resistant. This is what the future could...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...